Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Impact of the COVID-19 Pandemic on People Living with Rheumatoid Arthritis: Experiences and Preferences in Accessing Healthcare Across Five Countries.
Journal: Rheumatology and therapy
Published: September 19, 2023
An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars.
Journal: Journal of managed care & specialty pharmacy
Published: March 29, 2023
Overview of biosimilars for immune-mediated inflammatory diseases: summary of current evidence.
Journal: The American journal of managed care
Published: December 09, 2022
Biosimilars for immune-mediated inflammatory diseases: a managed care perspective.
Journal: The American journal of managed care
Published: December 09, 2022
Provider and patient knowledge gaps on biosimilars: insights from surveys.
Journal: The American journal of managed care
Published: December 09, 2022
Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.
Journal: Clinical pharmacology and therapeutics
Published: July 15, 2022
Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists.
Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
Published: July 23, 2020
A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis.
Journal: Osteoarthritis and cartilage
Published: July 20, 2020
Impact of COVID-19 on vulnerable patients with rheumatic disease: results of a worldwide survey.
Journal: RMD open
Published: June 25, 2020
Geographical variations in COVID-19 perceptions and patient management: a national survey of rheumatologists.
Journal: Seminars in arthritis and rheumatism
Published: May 26, 2020
US rheumatologists' beliefs and knowledge about biosimilars: a survey.
Journal: Rheumatology (Oxford, England)
Published: April 06, 2020
Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: August 29, 2019
Last Updated: 09/26/2026